(S)-1-(2,4-Difluorophenyl)Ethylamine Market – View in Detailed Research Report

MARKET INSIGHTS

Global (S)-1-(2,4-Difluorophenyl)Ethylamine market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.6 million in 2026 to USD 56.8 million by 2034, exhibiting a CAGR of 7.1% during the forecast period.

(S)-1-(2,4-Difluorophenyl)Ethylamine is a chiral amine compound characterized by a fluorinated aromatic ring system, widely recognized as a critical building block in pharmaceutical synthesis. Its enantiopure (S)-configuration makes it particularly valuable in the development of active pharmaceutical ingredients (APIs), where stereochemical precision directly influences drug efficacy and safety profiles. The compound finds primary application in the synthesis of antifungal agents, CNS-active drugs, and other specialty therapeutics requiring difluorophenyl moieties.

The market is experiencing steady growth driven by the expanding demand for chiral intermediates in drug discovery and the broader growth of the global pharmaceutical fine chemicals sector. Rising investments in asymmetric synthesis technologies and increasing outsourcing of API manufacturing to contract research and manufacturing organizations (CRMOs) are further supporting market expansion. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Fluorochem Ltd., among other specialty chemical manufacturers with established chiral chemistry portfolios.

Top 10 Companies in the (S)-1-(2,4-Difluorophenyl)Ethylamine Market

1. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: High‑purity chiral intermediates and custom synthesis services

Sigma‑Aldrich remains a global leader in the provision of chiral building blocks, offering a broad portfolio of (S)-configured amines with stringent enantiomeric excess specifications. Their integrated supply chain and GMP‑compliant manufacturing enable rapid delivery to pharmaceutical and research clients worldwide.

Sustainability & Growth Initiatives:

• Investment in green chemistry processes and reduced solvent usage.
• Expansion of custom synthesis capabilities to meet emerging API needs.
• Partnerships with leading biopharmaceutical companies for early‑stage development.

2. TCI Chemicals

Headquarters: Tokyo, Japan
Key Offering: Specialty chiral reagents and laboratory‑scale intermediates

TCI Chemicals supplies a wide range of high‑purity chiral compounds, including (S)-1‑(2,4‑difluorophenyl)ethylamine, to academic and industrial research sectors. Their focus on quality assurance and rapid batch production supports the needs of R&D labs and contract manufacturers.

Sustainability & Growth Initiatives:

• Implementation of renewable energy sources in production facilities.
• Development of scalable asymmetric hydrogenation routes.
• Strategic collaborations with CROs to expand market reach.

3. Fluorochem Ltd.

Headquarters: London, United Kingdom
Key Offering: Fluorinated chiral intermediates and custom synthesis

Fluorochem specializes in the synthesis of fluorinated chiral amines, providing high‑purity (S)-enantiomers for pharmaceutical and agrochemical applications. Their expertise in chiral resolution and catalytic processes ensures consistent supply to demanding clients.

Sustainability & Growth Initiatives:

• Adoption of flow‑chemistry platforms for safer, scalable production.
• Investment in biocatalytic methods to reduce environmental footprint.
• Expansion of product portfolio to include new fluorinated scaffolds.

4. Combi‑Blocks Inc.

Headquarters: San Diego, United States
Key Offering: Custom synthesis of chiral intermediates and API building blocks

Combi‑Blocks offers tailored synthesis solutions for (S)-configured amines, supporting pharmaceutical companies in early‑stage discovery and late‑stage manufacturing. Their flexible production model accommodates both small‑scale research and large‑scale commercial production.

Sustainability & Growth Initiatives:

• Development of enzyme‑based synthesis routes to enhance atom economy.
• Implementation of closed‑loop solvent recovery systems.
• Partnerships with academic institutions for technology transfer.

5. Jinan Hiteck Pharmaceutical Co., Ltd.

Headquarters: Jinan, China
Key Offering: GMP‑grade chiral intermediates and large‑scale production

Jinan Hiteck provides high‑purity (S)-1‑(2,4‑difluorophenyl)ethylamine at commercial scale, leveraging advanced asymmetric hydrogenation technologies. Their robust quality management system meets global regulatory requirements.

Sustainability & Growth Initiatives:

• Expansion of production capacity to meet rising API demand.
• Adoption of energy‑efficient manufacturing processes.
• Collaboration with CROs to support global drug development pipelines.

6. Hangzhou Keying Chem Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: Chiral resolution and asymmetric synthesis services

Hangzhou Keying specializes in chiral resolution of racemic mixtures and catalytic asymmetric synthesis, delivering (S)-enantiomers with high enantiomeric excess to pharmaceutical clients worldwide.

Sustainability & Growth Initiatives:

• Implementation of green solvents in resolution processes.
• Scale‑up of continuous flow reactors for efficient production.
• Strategic alliances with multinational pharmaceutical companies.

7. Zhengzhou Alfa Chemical Co., Ltd.

Headquarters: Zhengzhou, China
Key Offering: Fine‑chemical intermediates and custom synthesis

Alfa Chemical offers a portfolio of high‑purity chiral amines, including (S)-1‑(2,4‑difluorophenyl)ethylamine, supporting both research and commercial production needs.

Sustainability & Growth Initiatives:

• Adoption of renewable energy in manufacturing.
• Development of scalable enzymatic synthesis routes.
• Expansion of product catalog to meet emerging therapeutic demands.

8. Synthonix Inc.

Headquarters: San Francisco, United States
Key Offering: Advanced chiral synthesis and custom contract manufacturing

Synthonix provides tailored synthesis of (S)-configured intermediates, leveraging proprietary catalytic systems to achieve high enantiomeric purity.

Sustainability & Growth Initiatives:

• Investment in continuous flow chemistry platforms.
• Partnerships with biotech firms for early‑stage development.
• Implementation of closed‑loop recycling for solvents and reagents.

9. Nanjing Chemlin Chemical Industry Co., Ltd.

Headquarters: Nanjing, China
Key Offering: Chiral intermediates and specialty chemicals

Chemlin delivers high‑purity (S)-enantiomers for pharmaceutical and agrochemical applications, with a focus on scalable production and stringent quality control.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing processes.
• Expansion of product portfolio to include new fluorinated scaffolds.
• Collaboration with CROs for custom synthesis projects.

10. Capot Chemical Co., Ltd.

Headquarters: Chengdu, China
Key Offering: Custom synthesis and chiral resolution services

Capot offers specialized chiral resolution and catalytic synthesis solutions, providing (S)-1‑(2,4‑difluorophenyl)ethylamine to meet the high‑purity demands of the pharmaceutical sector.

Sustainability & Growth Initiatives:

• Adoption of green chemistry practices in synthesis.
• Investments in scalable flow‑chemistry infrastructure.
• Strategic partnerships with global pharma companies.

Download FREE Sample Report

Get Full Report

Outlook: The Future of (S)-1-(2,4-Difluorophenyl)Ethylamine Market

The (S)-1‑(2,4‑difluorophenyl)ethylamine market is poised for sustained growth, driven by the expanding pipeline of fluorinated small‑molecule therapeutics, particularly in CNS and oncology sectors. The increasing adoption of asymmetric synthesis technologies and biocatalytic routes is expected to reduce production costs and enhance scalability, further supporting market expansion. Additionally, the rise of contract manufacturing organizations (CMOs) and the shift toward outsourcing API production will continue to broaden the customer base for high‑purity chiral intermediates.

Future Trends Shaping the Market

• Advances in biocatalysis and engineered enzymes for cost‑effective chiral synthesis.
• Growth of continuous flow chemistry platforms for safer, scalable production.
• Increased focus on sustainability and green chemistry across the supply chain.
• Expansion of the agrochemical sector’s demand for fluorinated chiral amines.
• Enhanced regulatory requirements for enantiomeric purity driving premiumization of products.